Headway on Headaches: Major Grant Program Fuels Migraine Research for Women

Migraine is far more than a bad headache—it’s a debilitating neurological disease that affects nearly three times as many women as men. Now, a modern competitive grant program from the American Headache Society (AHS) and Pfizer is injecting up to $500,000 into research and quality improvement projects aimed at closing the care gap for women living with migraine.

Why Women Bear the Brunt of Migraine

Migraine ranks as the second leading cause of disability worldwide, and women shoulder the majority of its burden. Hormonal fluctuations—particularly around menstruation, pregnancy, and menopause—are known triggers, yet women’s migraine care often falls through the cracks. A 2024 report from the World Economic Forum identified migraine as the third-highest contributor to the global women’s health gap, trailing only premenstrual syndrome and depressive disorders. Addressing migraine in women could add an estimated $80 billion to the global economy by 2040, according to the same report.

“Investments addressing the women’s health gap could add years to life and life to years—and potentially boost the global economy by $1 trillion annually by 2040,” the report states. Yet, research has historically overlooked sex-based differences, with many preclinical studies relying on male animal models despite migraine’s female predominance.

A $500,000 Push for Patient-Centered Solutions

The AHS Headache & Migraine Competitive Grant Program: Migraine and Women’s Health is now accepting proposals for projects that improve care delivery, expand access, and drive measurable outcomes. Individual projects can request up to $200,000 in funding over two years, with a total available budget of $500,000.

Key Dates and Eligibility

• Letter of Intent (LOI) deadline: May 5, 2026
• Invitation to submit full proposal: June 30, 2026
• Full proposal deadline (by invitation only): August 28, 2026
• Award notification: October 30, 2026
• Project start date: December 1, 2026 or later

Proposals must focus on scalable, patient-centered solutions. Priority areas include:

• Screening and diagnosis of menstrual migraine in primary care or women’s health settings
• The relationship between calcitonin gene-related peptide (CGRP) and hormonal fluctuations
• Innovations in care delivery that address disparities in treatment access

Beyond Funding: A Community of Practice

Grantees will join a community of practice, sharing knowledge, tools, and best practices to amplify the impact of their operate. Projects are expected to produce measurable outcomes—such as improved diagnostic rates, reduced disability, or enhanced patient education—that can be replicated across healthcare systems.

Closing the Research Gap

Historically, women’s health conditions have been underfunded and understudied. The AHS-Pfizer initiative represents a critical step toward correcting that imbalance. By prioritizing research that directly addresses the unique needs of women with migraine, the program aims to transform care for millions.

“Migraine remains one of the most prevalent and disabling neurological diseases, significantly affecting quality of life, productivity, and overall health, especially among women,” the AHS states in its request for proposals. “Through this opportunity, we seek submissions that improve care delivery, expand access, and drive measurable outcomes for patients.”

Key Takeaways

• Migraine affects women at nearly three times the rate of men, yet research has historically overlooked sex-based differences.
• The AHS and Pfizer are offering up to $500,000 in grants for projects improving migraine care for women.
• Priority areas include menstrual migraine, CGRP-hormone interactions, and care delivery innovations.
• Letters of Intent are due May 5, 2026, with full proposals invited by June 30, 2026.
• Grantees will collaborate in a community of practice to share tools and outcomes.

FAQ

Who can apply for the grant?

The program is open to researchers, clinicians, and healthcare organizations. Applicants must submit a two-page Letter of Intent by May 5, 2026. Only those with accepted LOIs will be invited to submit full proposals.

What types of projects are eligible?

Projects must focus on quality improvement or research that enhances care for women with migraine. Examples include developing diagnostic tools, studying hormonal influences on migraine, or creating patient education programs.

How much funding is available?

Individual projects can request up to $200,000 over two years. The total available budget for the program is $500,000.

When will funding decisions be announced?

Award notifications are expected on October 30, 2026, with projects slated to begin December 1, 2026 or later.

The Road Ahead

As the May 5 deadline approaches, the migraine research community is poised for a wave of innovation. With women disproportionately affected by this condition, the AHS-Pfizer grant program offers a rare opportunity to turn scientific insights into real-world solutions. For patients, providers, and researchers alike, the message is clear: the time to close the women’s migraine care gap is now.